Literature DB >> 17167986

Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues.

S Nomura1, A Nakajima, S Ishimine, N Matsuhashi, T Kadowaki, M Kaminishi.   

Abstract

Gastric cancer cell lines express peroxisome proliferator-activated receptor gamma (PPARgamma), and treatment with PPARgamma ligands suppresses growth of subgroup of these cell lines. However, expression and subcellular distribution of PPARgamma in human gastric cancer tissues is still unknown. Therefore, expression and subcellular localization of PPARgamma were examined among different histological types of gastric cancer tissues. Immunohistochemical staining for PPARgamma was performed using biopsy specimens of human gastric cancer of various histological types, gastric adenomas, and intestinal metaplasia. All samples of intestinal metaplasia and most samples of gastric tumors, except for signet ring cell carcinoma, expressed PPARgamma in the epithelial cells. Most samples of signet ring cell cancer lacked PPARgamma expression. All samples of intestinal metaplasia expressed PPARgamma only in the cytosol. For adenoma, 90% was positive for PPARgamma in cytosol, and 40% was positive in nuclei, for well-differentiated adenocarcinoma, 80% was positive in cytosol, and 20% was positive in nuclei. For moderately differentiated adenocarcinomas, 70% was positive for cytosol, and 80% was positive for nuclei; for poorly differentiated adenocarcinoma, 30% was positive in cytosol, and 70% was positive in nuclei. The frequency of samples with positive cytosolic staining decreased as the differentiation stage turned from intestinal metaplasia to adenoma, well-, moderately-, and poorly-differentiated cancers. Simultaneously, there was a tendency toward an increased frequency of samples with positive nuclear PPARgamma staining as the differentiation stage transformed from intestinal metaplasia to poorly-differentiated cancer. There was a striking difference in subcellular localization according to the differentiation levels of gastric dysplastic cells. The findings also supported an intestinal metaplasia-adenoma-well-differentiated gastric cancer sequence, and signet ring cell cancer was suggested to be of a different lineage from other types of gastric cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17167986

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  9 in total

1.  The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor γ through spatial relocalization at helix 7 of its ligand-binding domain.

Authors:  Elke Burgermeister; Teresa Friedrich; Ivana Hitkova; Ivonne Regel; Henrik Einwächter; Wolfgang Zimmermann; Christoph Röcken; Aurel Perren; Matthew B Wright; Roland M Schmid; Rony Seger; Matthias P A Ebert
Journal:  Mol Cell Biol       Date:  2011-06-20       Impact factor: 4.272

2.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

3.  Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition.

Authors:  Yu-Wei Dong; Xing-Peng Wang; Kai Wu
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

4.  The Role of PPARγ in Helicobacter pylori Infection and Gastric Carcinogenesis.

Authors:  Jong-Min Lee; Sung Soo Kim; Young-Seok Cho
Journal:  PPAR Res       Date:  2012-08-09       Impact factor: 4.964

5.  PPARgamma and MEK Interactions in Cancer.

Authors:  Elke Burgermeister; Rony Seger
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

Review 6.  Chemotherapy and chemoprevention by thiazolidinediones.

Authors:  Eleonore Fröhlich; Richard Wahl
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

7.  Peroxisome proliferator-activated receptor-α expression is associated with histological type in human gastric carcinoma.

Authors:  Tatsuya Morinishi; Yasunori Tokuhara; Kazuki Kajihara; Shunsei Kawakami; Shinichi Tanaka; Hiroyuki Ohsaki; Toru Matsunaga; Emi Ibuki; Eiichiro Hirakawa
Journal:  Mol Clin Oncol       Date:  2021-12-24

8.  Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway.

Authors:  Luqi Wang; Yue Wang; Andy Chen; Meghana Teli; Rika Kondo; Aydin Jalali; Yao Fan; Shengzhi Liu; Xinyu Zhao; Amanda Siegel; Kazumasa Minami; Mangilal Agarwal; Bai-Yan Li; Hiroki Yokota
Journal:  FASEB J       Date:  2019-10-04       Impact factor: 5.834

9.  The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers.

Authors:  Barbara Delage; Anne Rullier; Maylis Capdepont; Eric Rullier; Pierrette Cassand
Journal:  Nutr J       Date:  2007-09-03       Impact factor: 3.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.